Despite the fact that a Trip13‐specific inhibitor (DCZ0415) has been recently described, showing a potent antitumor activity in multiple myeloma in vitro and in vivo,[19] it is not expected to be in the clinics any time soon. This evidence concerns the gene TRIP13 and plasma cell myeloma.